Challenges associated with metabolic syndrome
1Department of Pharmacy Practice, Philadelphia College of Pharmacy and Science, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania 19104-4495, USA.
Insights
Cardiovascular disease (CVD) remains a leading cause of death, with metabolic syndrome significantly increasing risk. Managing key factors like obesity, hypertension, and diabetes is crucial for prevention.
Area of Science:
- Cardiology
- Endocrinology
- Public Health
Background:
- Cardiovascular disease (CVD) is a leading cause of death in the US, with substantial economic burden.
- Despite therapeutic advances, residual CVD risk persists, partly due to the rising prevalence of metabolic syndrome.
- Metabolic syndrome, characterized by abdominal obesity, dyslipidemia, hypertension, and hyperglycemia, significantly elevates risks for atherosclerotic CVD and type 2 diabetes.
Purpose of the Study:
- To highlight the significant public health challenge posed by cardiovascular disease and metabolic syndrome.
- To underscore the association between metabolic syndrome, its underlying risk factors (abdominal obesity, insulin resistance), and cardiovascular events.
- To emphasize current therapeutic strategies and the need for further research in managing metabolic syndrome.
Main Methods:
- Literature review and synthesis of epidemiological data on CVD and metabolic syndrome prevalence and costs.
- Analysis of the interrelationship between metabolic syndrome components and cardiovascular risk factors.
- Review of current clinical guidelines for managing metabolic syndrome and its associated risk factors.
Main Results:
- Cardiovascular disease claims approximately 2500 American lives daily, exceeding the next four leading causes combined.
- Metabolic syndrome affects roughly 47 million US adults, with abdominal obesity and insulin resistance as primary drivers.
- Individuals with metabolic syndrome face increased risks of atherosclerotic CVD and type 2 diabetes.
Conclusions:
- Lifestyle modification targeting major CVD risk factors (lipids, blood pressure, diabetes) is the recommended first-line therapy for metabolic syndrome.
- Current management of metabolic syndrome should align with established clinical guidelines for cardiovascular risk factors.
- Further research is needed to define optimal therapeutic approaches for individuals with metabolic syndrome.
Abstract:
Approximately 2500 Americans die from cardiovascular disease (CVD) each day. Each year, CVD claims more lives than the next four leading causes of death combined. Direct and indirect costs of CVD are estimated to be Dollars 403.1 billion in 2006. Despite advancements in conventional therapy, the residual risk of CVD continues to rise. One component of the cardiometabolic risk is metabolic syndrome. Metabolic syndrome is a constellation of interrelated risk factors of metabolic origin including abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose level, and prothrombotic and proinflammatory states that promote atherosclerotic CVD and increase the risk of type 2 diabetes mellitus. Approximately 47 million residents of the United States have metabolic syndrome. Abdominal obesity and insulin resistance appear to be its predominant underlying risk factors. Abdominal adiposity is considered high-risk fat, and it is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension, and prothrombotic and/or proinflammatory states. Despite notable advances in cardiovascular risk management, the prevalence of cardiovascular events and type 2 diabetes remains high. First-line therapy for individuals with metabolic syndrome should be directed to the major CVD risk factors, namely, elevated low-density lipoprotein cholesterol levels, hypertension, and diabetes, and it should emphasize lifestyle modification. Until additional research better defines the most appropriate therapies, conventional cardiovascular risk factors, such as lipid levels, blood pressure, and diabetes, should be managed in individuals with metabolic syndrome according to nationally accepted clinical guidelines.
Related Concept Videos
01:26Type II Diabetes I: Introduction
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:24Type II Diabetes II: Pathophysiology
01:30Coronary Artery Disease I: Introduction
01:22Complications of Diabetes Mellitus
01:19Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...